Sale

Alzheimer’s Drugs Market

Global Alzheimer’s Drugs Market Size, Share, Forecast: By Drug Class: Memantine, Cholinergic, Combined Drug, Others; By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospital Pharmacies, Others; Regional Analysis; Market Dynamics: SWOT Analysis, Porter’s Five Forces Analysis; Competitive Landscape; 2024-2032

Global Alzheimer’s Drugs Market Outlook

The global Alzheimer’s Drugs market is expected to grow at a CAGR of 6.8% during the period 2024-2032. The global market is expected to be driven by ageing global population and need for effective solutions to manage Alzheimer’s. Significant regions include UAE, Qatar, USA, China, Germany, France, UK and Switzerland.

 

alzheimers-drugs-market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Market Likely to be Driven by Ageing Global Population and Need to Effectively Manage the Disease

Despite significant efforts towards developing a cure, Alzheimer’s remains incurable. However, there has been some progress in the fight against the condition. With the help of drugs, mental performance may be stabilized and progression of symptoms slowed. With medicinal treatment, several concomitant therapies are used today which seek to promote patients’ mental faculties or preserve those capabilities for as long as possible, enhancing overall quality of life and relieving the burden on relatives.

Alzheimer’s disease, named after the neurologist Alois Alzheimer, is the most common form of dementia, affecting nearly sixty to seventy percent of approximately 50 million dementia patients across the globe. It is a neurodegenerative disease (alongside Parkinson’s disease). The diseases are followed by a progressive loss of nerve cells and cell functions, which at one point of time becomes so great that it becomes impossible for the brain to compensate. The global Alzheimer’s drugs market is expected to be driven by ageing global population and the need for effective solutions to manage the disease. Depending on the stage (mild, moderate, severe), symptoms of the disease may include disorientation, memory loss, problems with speech, difficulty carrying out familiar activities, and changes in personality. These disorders may differ in severity, and increase as the disease progresses. Thus, everyday life becomes impossible to manage alone and the patient becomes increasingly dependent on support. This way, the quality of life of those affected and their relatives is considerably reduced.

 

Treatment Systems Helpful in Management of the Disease Expected to Boost Market Growth

A modern therapeutic procedure that has become available recently is Transcranial Pulse Stimulation (TPS®). TPS seeks to promote/maintain mental capabilities of people with Alzheimer’s disease, and is used to treat patients with mild to moderate Alzheimer’s. Acoustic pulses produced outside the body are introduced particularly into the brain regions needing treatment; treatment is administered on an outpatient basis. Such developments are likely to boost the global Alzheimer’s drugs market. TPS is safe and uncomplicated, with an average treatment duration of 30 minutes per session; one course of treatment entails six sessions over two weeks. TPS has been quite successful. In 2023, the 100th NEUROLITH® system was installed at the Lengg Clinic in Zurich, Switzerland.

While Alzheimer’s cannot be cured and its progression not stopped, through therapies and medicines, the progression of the disease may be slowed and symptoms alleviated. The aim of treatment is to decrease behavioural disorders and improve general patient well-being. In the early stages, a well-coordinated combination of therapeutic measures could significantly contribute to maintaining patient independence and quality of life.

Treatments available for the condition include Aducanumab/Aduhelm™, Donepezil/Aricept®, Galantamine/Razadyne®, Rivastigmine/Exelon®, Memantine/Namenda®, and Memantine + Donepezil/Namzaric®. Suvorexant/Belsomra® is used to treat non-cognitive symptoms (behavioral and psychological).

 

alzheimers-drugs-market-by-segmentation

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Alzheimer’s Drugs Market Segmentation

By drug class, the global Alzheimer’s drugs market is segmented into:

  • Memantine
  • Cholinergic
  • Combined Drug
  • Others

By distribution channel, the market is classified into:

  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
  • Others

By region, the market is divided into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

alzheimers-drugs-market-by-region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Key Industry Players in the Alzheimer’s Drugs Market

The report presents a detailed analysis of the following key players in the global Alzheimer’s drugs market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Merck Sharp & Dohme Corp.
  • Biogen Inc.
  • AbbVie Inc.
  • Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class
  • Distribution Channel
  • Region
Breakup by Drug Class
  • Memantine
  • Cholinergic
  • Combined Drug
  • Others
Breakup by Distribution Channel
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
  • Others
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Merck Sharp & Dohme Corp.
  • Biogen Inc.
  • AbbVie Inc.
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Regional
7    Opportunities and Challenges in the Market
8    Global Alzheimer’s Drugs Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Alzheimer’s Drugs Historical Market (2018-2023) 
    8.3    Global Alzheimer’s Drugs Market Forecast (2024-2032)
    8.4    Global Alzheimer’s Drugs Market by Drug Class
        8.4.1    Memantine
            8.4.1.1    Historical Trend (2018-2023)
            8.4.1.2    Forecast Trend (2024-2032)
        8.4.2    Cholinergic
            8.4.2.1    Historical Trend (2018-2023)
            8.4.2.2    Forecast Trend (2024-2032)
        8.4.3    Combined Drug
            8.4.3.1    Historical Trend (2018-2023)
            8.4.3.2    Forecast Trend (2024-2032)
        8.4.4    Others
    8.5    Global Alzheimer’s Drugs Market by Distribution Channel
        8.5.1    Retail Pharmacies
            8.5.1.1    Historical Trend (2018-2023)
            8.5.1.2    Forecast Trend (2024-2032)
        8.5.2    Online Pharmacies
            8.5.2.1    Historical Trend (2018-2023)
            8.5.2.2    Forecast Trend (2024-2032)
        8.5.3    Hospital Pharmacies
            8.5.3.1    Historical Trend (2018-2023)
            8.5.3.2    Forecast Trend (2024-2032)
        8.5.4    Others    
    8.6    Global Alzheimer’s Drugs Market by Region
        8.6.1    North America
            8.6.1.1    Historical Trend (2018-2023) 
            8.6.1.2    Forecast Trend (2024-2032)
        8.6.2    Europe
            8.6.2.1    Historical Trend (2018-2023) 
            8.6.2.2    Forecast Trend (2024-2032)
        8.6.3    Asia Pacific
            8.6.3.1    Historical Trend (2018-2023) 
            8.6.3.2    Forecast Trend (2024-2032)
        8.6.4    Latin America
            8.6.4.1    Historical Trend (2018-2023) 
            8.6.4.2    Forecast Trend (2024-2032)
        8.6.5    Middle East and Africa
            8.6.5.1    Historical Trend (2018-2023) 
            8.6.5.2    Forecast Trend (2024-2032)
9    North America Alzheimer’s Drugs Market Analysis
    9.1    United States of America 
        9.1.1    Historical Trend (2018-2023) 
        9.1.2    Forecast Trend (2024-2032)
    9.2    Canada
        9.2.1    Historical Trend (2018-2023) 
        9.2.2    Forecast Trend (2024-2032)
10    Europe Alzheimer’s Drugs Market Analysis
    10.1    United Kingdom
        10.1.1    Historical Trend (2018-2023) 
        10.1.2    Forecast Trend (2024-2032)
    10.2    Germany
        10.2.1    Historical Trend (2018-2023) 
        10.2.2    Forecast Trend (2024-2032)
    10.3    France
        10.3.1    Historical Trend (2018-2023) 
        10.3.2    Forecast Trend (2024-2032)
    10.4    Italy
        10.4.1    Historical Trend (2018-2023) 
        10.4.2    Forecast Trend (2024-2032)
    10.5    Others
11    Asia Pacific Alzheimer’s Drugs Market Analysis
    11.1    China
        11.1.1    Historical Trend (2018-2023) 
        11.1.2    Forecast Trend (2024-2032)
    11.2    Japan
        11.2.1    Historical Trend (2018-2023) 
        11.2.2    Forecast Trend (2024-2032)
    11.3    India
        11.3.1    Historical Trend (2018-2023) 
        11.3.2    Forecast Trend (2024-2032)
    11.4    ASEAN
        11.4.1    Historical Trend (2018-2023) 
        11.4.2    Forecast Trend (2024-2032)
    11.5    Australia
        11.5.1    Historical Trend (2018-2023) 
        11.5.2    Forecast Trend (2024-2032)
    11.6    Others
12    Latin America Alzheimer’s Drugs Market Analysis
    12.1    Brazil
        12.1.1    Historical Trend (2018-2023) 
        12.1.2    Forecast Trend (2024-2032)
    12.2    Argentina
        12.2.1    Historical Trend (2018-2023) 
        12.2.2    Forecast Trend (2024-2032)
    12.3    Mexico
        12.3.1    Historical Trend (2018-2023) 
        12.3.2    Forecast Trend (2024-2032)
    12.4    Others
13    Middle East  and Africa Alzheimer’s Drugs Market Analysis
    13.1    Saudi Arabia
        13.1.1    Historical Trend (2018-2023) 
        13.1.2    Forecast Trend (2024-2032)
    13.2    United Arab Emirates
        13.2.1    Historical Trend (2018-2023) 
        13.2.2    Forecast Trend (2024-2032)
    13.3    Nigeria
        13.3.1    Historical Trend (2018-2023) 
        13.3.2    Forecast Trend (2024-2032)
    13.4    South Africa
        13.4.1    Historical Trend (2018-2023) 
        13.4.2    Forecast Trend (2024-2032)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
    14.3    Key Indicators for Demand
    14.4    Key Indicators for Price
15    Value Chain Analysis
16    Competitive Landscape

    16.1    Market Structure
    16.2    Company Profiles
        16.2.1    F. Hoffmann-La Roche Ltd
            16.2.1.1    Company Overview
            16.2.1.2    Product Portfolio
            16.2.1.3    Demographic Reach and Achievements
            16.2.1.4    Certifications
        16.2.2    Novartis AG
            16.2.2.1    Company Overview
            16.2.2.2    Product Portfolio
            16.2.2.3    Demographic Reach and Achievements
            16.2.2.4    Certifications
        16.2.3    Merck Sharp & Dohme Corp.
            16.2.3.1    Company Overview
            16.2.3.2    Product Portfolio
            16.2.3.3    Demographic Reach and Achievements
            16.2.3.4    Certifications
        16.2.4    Biogen Inc.
            16.2.4.1    Company Overview
            16.2.4.2    Product Portfolio
            16.2.4.3    Demographic Reach and Achievements
            16.2.4.4    Certifications
        16.2.5    AbbVie Inc.
            16.2.5.1    Company Overview
            16.2.5.2    Product Portfolio
            16.2.5.3    Demographic Reach and Achievements
            16.2.5.4    Certifications
        16.2.6    Others
17    Key Trends and Developments in the Market

 

List of Key Figures and Tables

1.    Global Alzheimer’s Drugs Market: Key Industry Highlights, 2017 and 2021
2.    Global Alzheimer’s Drugs Historical Market: Breakup by Drug Class (USD Million), 2018-2023
3.    Global Alzheimer’s Drugs Market Forecast: Breakup by Drug Class (USD Million), 2024-2032
4.    Global Alzheimer’s Drugs Historical Market: Breakup by Distribution Channel (USD Million), 2018-2023
5.    Global Alzheimer’s Drugs Market Forecast: Breakup by Distribution Channel (USD Million), 2024-2032
6.    Global Alzheimer’s Drugs Historical Market: Breakup by Region (USD Million), 2018-2023
7.    Global Alzheimer’s Drugs Market Forecast: Breakup by Region (USD Million), 2024-2032
8.    North America Alzheimer’s Drugs Historical Market: Breakup by Country (USD Million), 2018-2023
9.    North America Alzheimer’s Drugs Market Forecast: Breakup by Country (USD Million), 2024-2032
10.    Europe Alzheimer’s Drugs Historical Market: Breakup by Country (USD Million), 2018-2023
11.    Europe Alzheimer’s Drugs Market Forecast: Breakup by Country (USD Million), 2024-2032
12.    Asia Pacific Alzheimer’s Drugs Historical Market: Breakup by Country (USD Million), 2018-2023
13.    Asia Pacific Alzheimer’s Drugs Market Forecast: Breakup by Country (USD Million), 2024-2032
14.    Latin America Alzheimer’s Drugs Historical Market: Breakup by Country (USD Million), 2018-2023
15.    Latin America Alzheimer’s Drugs Market Forecast: Breakup by Country (USD Million), 2024-2032
16.    Middle East and Africa Alzheimer’s Drugs Historical Market: Breakup by Country (USD Million), 2018-2023
17.    Middle East and Africa Alzheimer’s Drugs Market Forecast: Breakup by Country (USD Million), 2024-2032
18.    Global Alzheimer’s Drugs Market Structure

Key Questions Answered in the Report

The market is projected to grow at a CAGR of 6.8% between 2024 and 2032.

The only disease-modifying drug currently approved to treat Alzheimer's is aducanumab. This treatment, which targets the protein beta-amyloid and works as an immunotherapy, helps to lessen amyloid plaques, which are brain lesions connected to Alzheimer's disease.

The major drivers of the global Alzheimer’s drugs market include the need for effective solutions to manage Alzheimer’s, development of digital tools, improving diagnostic capabilities, evolving healthcare infrastructure, and raising awareness regarding Alzheimer’s disease.

The ageing global population and growing cases of Alzheimer’s worldwide are the key industry trends propelling the market's growth.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

Based on drug class, the market is classified into memantine, cholinergic, and combined drug, among others.

The several distribution channels in the market are retail pharmacies, online pharmacies, and hospital pharmacies, among others.

Drugs including sertraline, fluoxetine, nortriptyline, citalopram (Celexa), and fluoxetine (Prozac) (Zoloft) keep Alzheimer's calm. Drowsiness, dry mouth, constipation, and anxiety are some of these medications' side effects.

The major players in the industry are F. Hoffmann-La Roche Ltd, Novartis AG, Merck Sharp & Dohme Corp., Biogen Inc., and AbbVie Inc., among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER